Influenza vaccines for preventing cardiovascular disease

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 5, 2015, Pages

  Clar, Christine ^a   Oseni, Zainab ^b   Flowers, Nadine ^b   Keshtkar Jahromi, Maryam ^c   Rees, Karen ^b  

^a Division of Health Sciences ^*  (Germany)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PLACEBO;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COUGHING; DECREASED APPETITE; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FATIGUE; FOLLOW UP; HEADACHE; HEART INFARCTION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; ISCHEMIC HEART DISEASE; MYALGIA; NOSE OBSTRUCTION; OUTCOME ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RHINORRHEA; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; SORE THROAT; SYSTEMATIC REVIEW; CORONARY DISEASE; INFLUENZA, HUMAN; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CORONARY DISEASE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION;

EID: 84940687787     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005050.pub3     Document Type: Review

References (80)

1. De Villiers PJT, Steele AD, Hiemstra LA, Rappaport R, Dunning AJ, Gruber WC, et al. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine 2009;28:228-34.
2. Ciszewski A, Bilinska ZT, Brydak LB, Kepka C, Kruk M, Romanowska M, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. European Heart Journal 2008;29:1350-8.
3. Ciszewski A, Bilinska ZT, Kepka C, Kruk M, Ksiezycka-Majczynska E, Ruzyllo W. The protective effect of influenza vaccination on the clinical course of coronary disease in patients with acute coronary syndromes treated by primary PCI - A report from FLUCAD study. Postepy w Kardiologii Interwencyjnej 2010;6:6-11.
4. Gurfinkel EP, Leon de la Fuente R, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. European Heart Journal 2004;25(1):25-31.
5. Gurfinkel EP, de la Fuente RL. Two-year follow-up of the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Registry. Texas Heart Institutional Journal 2004;31(1):28-32.
6. Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation 2002;105(8):2143-7.
7. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994;272:1661-5.
8. Keshtkar-Jahromi M, Vakili H, Rahnavardi M, Gholamin S, Razavi SM, Eskandari A, et al. Antibody response to influenza immunization in coronary artery disease patients: a controlled trial. Vaccine 2009;28(1):110-3. [PUBMED: 19819210]
9. Keshtkar-Jahromi M, Vakili H, Rahnavardi M, Gholamin S, Razavi SM, Eskandari A, et al. The efficacy of influenza vaccination in reducing cardiovascular events in patients with coronary artery diseases: IVCAD study. Clinical Microbiology and Infection 2009;15:S396.
10. Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B, Fogarty C, et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: A phase III, placebo-controlled, randomized study. Journal of Infectious Diseases 2011;203:1729-38.
11. Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. European Heart Journal 2011;32:1730-5.
12. Wu J, Li W, Wang HQ, Chen JT, Lv M, Zhou JC, et al. A rapid immune response to 2009 influenza a(H1N1) vaccines in adults: a randomized, double-blind, controlled trial. Journal of Infectious Diseases 2010;202:675-80.
13. Allsup S, Haycox A, Regan M, Gosney M. Is influenza vaccination cost effective for healthy people between ages 65 and 74 years? A randomised controlled trial. Vaccine 2004;23(5):639-45.
14. Baluch A, Humar A, Egli A, Hoschler K, Campbell P, Urschel S, et al. A randomized controlled trial of high-dose intradermal vs. standard intramuscular influenza vaccine in solid organ transplant recipients. American Journal of Transplantation 2012;12:53-4.
15. Blumberg EA, Fitzpatrick J, Stutman PC, Hayden FG, Brozena SC. Safety of influenza vaccine in heart transplant recipients. Journal of Heart and Lung Transplantation 1998;17(11):1075-80. [: CN-00157991]
16. Brydak L B, Romanowska M, Nowak I, Ciszewski A, Bilinska Z T. Antibody response to influenza vaccine in coronary artery disease: a substudy of the FLUCAD study. Medical Science Monitor 2009;15:PH85-91.
17. Christenson B, Pauksen K, Sylvan SP. Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity. Virology Journal 2008;5:52.
18. De Bernardi Di Valserra M, Zanasi A, Ragusa S, Glück R, Herzog C. An open-label comparison of the immunogenicity and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults. Clinical Therapeutics 2002;24(1):100-11. [: CN-00388484]
19. DiazGranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine 2013;31:861-6.
20. Falchetti G, Magnani E. Flu vaccine in patients with orthotopic heart transplantation. Italian Heart Journal: Official Journal of the Italian Federation Cardiology 2000;1(Suppl 6):25. [: CN-00336125]
21. Falsey AR, Walsh EE, Capellan J, Gravenstein S, Zambon M, Yau E, et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals. Journal of Infectious Diseases 2008;198:1317-26.
22. Farrow PR, Nicholson KG. Lack of effect of influenza and pneumococcal vaccines on anticoagulation by warfarin. Journal of Infection 1984;9(2):157-60. [: CN-00036161]
23. Fletcher TJ, Tunnicliffe WS, Hammond K, Roberts K, Ayres JG. Simultaneous immunisation with influenza vaccine and pneumococcal polysaccharide vaccine in patients with chronic respiratory disease. BMJ 1997; Vol. 314:1663-5.
24. Garcia Vallejo R, Lazaro Mari MP, Quintana Bravo MA. [Impact of an anti-flu vaccination strategy for prevention of cardiovascular diseases]. Revista de Calidad Asistencial 2009;24:11-5.
25. Grau AJ, Fischer B, Barth C, Ling P, Lichy C, Buggle F. Influenza vaccination is associated with a reduced risk of stroke. Stroke 2005;36:1501-6.
26. Gurfinkel E, Mautner B. [Secondary prevention of coronary artery disease. Flu vaccinations and new evidence of the role of infection in acute coronary syndromes]. Revista Espanola de Cardiologia 2002;55:1009-12.
27. Honkanen P, Laara E, Pyhala R, Kivela SL, Makela PH. Comparison of two vaccination programmes in preventing influenza-related hospitalization among the elderly during two consecutive seasons. Scandinavian Journal of Infectious Diseases 2006;38:506-11.
28. Hui SL, Chu LW, Peiris JS, Chan KH, Chu D, Tsui W. Immune response to influenza vaccination in community-dwelling Chinese elderly persons. Vaccine 2006;24(25):5371-80. [: CN-00565486]
29. Hui SL, Chu LW, Peiris JS, Chan KH, Chu D, Tsui W. Immune response to influenza vaccination in community-dwelling Chinese elderly persons. Vaccine 2006;24:5371-80.
30. Iorio A, Basileo M, Marcucci M, Guercini F, Camilloni B, Paccamiccio E, et al. Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study. Archives of Internal Medicine 2010;170:609-16.
31. Jackson LA, Holmes SJ, Mendelman PM, Huggins L, Cho I, Rhorer J. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 1999;17(15-16):1905-9. [: CN-00162346]
32. Kalyagin AN. Decrease of progressing chronic heart failure and rheumatic heart disease by vaccination of patients against influenza. International Journal of Rheumatic Diseases 2012;15:129.
33. Langley JM, Aoki F, Ward BJ, McGeer A, Angel JB, Stiver G, et al. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. Vaccine 2011;29:1921-8.
34. Li R, Fang H, Li Y, Liu Y, Pellegrini M, Podda A. Safety and immunogenicity of an MF59[trademark]-adjuvanted subunit influenza vaccine in elderly Chinese subjects. 2TN: NCT00310648/ClinicalTrials.gov 2008; Vol. 5:2TN: NCT00310648/ClinicalTrials.gov.
35. Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. British Journal of Haematology 2005;130(1):96-8. [: CN-00522802]
36. MacIntyre R. A randomised controlled clinical trial of influenza vaccine in the prevention of recurrent ischaemic vascular events in patients with recent myocardial infarction, a transient ischaemic attack or with an ischaemic cerebrovascular event (stroke) aged between 40-64 years of age. Australian New Zealand Trials Registry 2007; Vol. ACTRN12607000197437.
37. Madjid M, Aboshady I, Awan I, Litovsky S, Casscells SW. Influenza and cardiovascular disease - Is there a causal relationship?. Texas Heart Institute Journal 2004;31:4-13.
38. Magnani G, Falchetti E, Pollini G, Reggiani LB, Grigioni F, Coccolo F, et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. Journal of Heart and Lung Transplantation 2005;24(5):588-92. [: CN-00521953]
39. Magnani G, Falchetti E, Pollini G, Reggiani LB, Grigioni F, Coccolo F, et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. Journal of Heart & Lung Transplantation 2005;24:588-92.
40. McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. The Lancet Infectious Diseases 2013;13:485-96.
41. McNeil SA, Noya F, Dionne M, Predy G, Meekison W, Ojah C, et al. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. Vaccine 2007;25:3464-74.
42. Morales A, Salazar JA, Salazar Y, Garcia A, Arnoux S, Arancibia A, et al. A randomized controlled trial comparing split and subunit influenza vaccines in adults in Columbia. Medicina 2003;63:197-204.
43. Musto P, Carotenuto M. Vaccination against influenza in multiple myeloma. British Journal of Haematology 1997;97(2):505-6. [: CN-00139900]
44. Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999;282:137.
45. Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. New England Journal of Medicine 2006;355:2513-22.
46. Plasai V, Lertmaharit S, Viputsiri OA, Pongpanich S, Panichpathompong U, Tarnmaneewongse V, et al. Influenza vaccination among the elderly in Bangkok. Southeast Asian Journal of Tropical Medicine & Public Health 2006;37 Suppl 3:140-4.
47. Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ. Subunit Influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. Journal of Infectious Diseases 2009;200:849-57.
48. Scheifele DW, Duval B, Russell ML, Warrington R, DeSerres G, Skowronski DM, et al. Ocular and respiratory symptoms attributable to inactivated split influenza vaccine: evidence from a controlled trial involving adults. Clinical Infectious Diseases 2003;36:850-7.
49. Scheifele DW, Dionne M, Ward BJ, Cooper C, Vanderkooi OG, Li Y, et al. Safety and immunogenicity of 2010-2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: results of a randomized trial. Human Vaccines and Immunotherapeutics 2013;9:136-43.
50. Schwarz TF, Flamaing J, Rumke HC, Penzes J, Juergens C, Wenz A, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged >=65 years. Vaccine 2011;29:5195-202.
51. Sinnecker H, Bernigau W, Woratz G, Muller D, Bigl S, Bog R, et al. Investigations into excess mortality and into the effectiveness of prophylactic influenza vaccinations in patients with chronic cardiovascular disease. Zeitschrift fur Klinische Medizin 1987;42(26):2353-7. [: CN-00255730]
52. Vardeny O, Hermanson MP, Moran JM, Johnson MR, Sweitzer NK. A randomized study of double-dose versus single-dose influenza vaccination in patients with heart failure. Circulation 2011;124:A16608.
53. Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, Liang XF, et al. A novel influenza A (H1N1) vaccine in various age groups. New England Journal of Medicine 2009;361:2414-23.
54. Zimmermann U, Gavazzi G, Richard P, Eymin C, Soubeyrand B, Baudin M. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged >=60 years: an open-label, randomised trial. Vaccine 2013;31:1496-502.
55. Loeb M. Influenza vaccine to prevent adverse vascular events: a pilot study. http://clinicaltrials.gov/ct2/show/NCT01945268.
56. Advisory Committee on Immunization Practices. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season. MMWR. Morbidity and Mortality Weekly Report 2012;61(32):613-8. [PUBMED: 22895385]
57. European Centre for Disease Prevention and Control. Influenza vaccination. http://www.ecdc.europa.eu/en/healthtopics/seasonal_influenza/vaccines/Pages/influenza_vaccination.aspx 2014.
58. Centers for Disease Control and Prevention. People at high risk of developing flu-related complications. http://www.cdc.gov/flu/about/disease/high_risk.htm 2015.
59. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR. Recommendations and Reports: Morbidity and Mortality Weekly Report. Recommendations and Reports/Centers for Disease Control 2010;59(RR-8):1-62. [PUBMED: 20689501]
60. Hebsur S, Vakil E, Oetgen WJ, Kumar PN, Lazarous DF. Influenza and coronary artery disease: exploring a clinical association with myocardial infarction and analyzing the utility of vaccination in prevention of myocardial infarction. Reviews in Cardiovascular Medicine 2014;15:168-75.
61. Jefferson TO, Rivetti D, Deeks JJ, Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD001269.pub3]
62. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
63. Loomba RS, Aggarwal S, Shah PH, Arora RR. Influenza vaccination and cardiovascular morbidity and mortality: analysis of 292, 383 patients. Journal of Cardiovascular Pharmacology and Therapeutics 2012;17:277-83.
64. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine 2006;3(11):e442.
65. Naghavi M, Barlas Z, Siadaty S, Naguib S, Madjid M, Casscells W. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000;102:3039-45.
66. Nelson JC, Jackson ML, Jackson LA. Effectiveness of influenza vaccination. New England Journal of Medicine 2007;357:2728-9.
67. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. New England Journal of Medicine 2003;348:1322-32.
68. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. New England Journal of Medicine 2007;357:1373-81.
69. Rogers KC, Wallace JP, Foster SL, Finks SW. Annual influenza vaccination: offering protection beyond infection. Southern Medical Journal 2012;105:379-86.
70. Simonsen L Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infectious Diseases 2007;7:658-66.
71. Siscovick DS, Raghunathan TE, Lin D, Weinmann S, Arbogast P, Lemaitre RN, et al. Influenza vaccination and the risk of primary cardiac arrest. American Journal of Epidemiology 2000;152:674-7.
72. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. New England Journal of Medicine 2004;351:2611-18.
73. Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 2013;310:1711-20.
74. UK Department of Health. The national flu immunisation programme 2014/15. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/316007/FluImmunisationLetter2014_accessible.pdf 2014.
75. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infectious Diseases 2009;9:601-10.
76. Warren-Gash C, Bhaskaran K, Hayward A, Leung GM, Lo SV, Wong CM, et al. Circulating influenza virus, climatic factors, and acute myocardial infarction: a time series study in England and Wales and Hong Kong. Journal of Infectious Diseases 2011;203:1710-8.
77. Warren-Gash C, Hayward AC, Hemingway H, Denaxas S, Thomas SL, Timmis AD, et al. Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. Journal of Infectious Diseases 2012;206:1652-9.
78. WHO Global Status Report on Non Communicable Diseases 2010. Geneva: World Health Organization, 2011.
79. WHO Cardiovascular Diseases (CVDs). Factsheet Number 317 Updated March 2013.
80. WHO SAGE Working Group. Background paper on influenza vaccines and immunization. http://www.who.int/immunization/sage/meetings/2012/april/1_Background_Paper_Mar26_v13_cleaned.pdf.